Skip to main content

All Articles

Survey Reveals Drawbacks to Participation in ACA Exchanges

By Rosemary Frei, MSc

Affordable Care Act

August 2014, Vol 4, No 5

FDA Approvals, News & Updates

August 2014, Vol 4, No 5

New Clinical Trials Under Way

Clinical Trials Tracker

August 2014, Vol 4, No 5

The 90-Day Grace Period: What Providers Need to Know

By Sydney Abbott, JD

August 2014, Vol 4, No 5

New IRA Rollover Rules Issued by the IRS

By Lawrence B. Keller, CFP, CLU, ChFC, RHU, LUTCF

Financial Management, Practice Management

August 2014, Vol 4, No 5

FDA-Approved Medications for the Treatment of Leukemia

August 2014, Vol 4, No 5

Zykadia (Ceritinib) Approved for the Treatment of Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer

By Lisa A. Raedler, PhD, RPh

August 2014, Vol 4, No 5

Imbruvica (Ibrutinib) the First Bruton’s Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia

By Lisa A. Raedler, PhD, RPh

June 2014, Vol 4, No 4

Imbruvica YOU&i Access Program and Support for Patients

June 2014, Vol 4, No 4

Providing Social Support to Patients with Cancer

Best Practices, Practice Management

June 2014, Vol 4, No 4

Page 276 of 298